Trials / Completed
CompletedNCT06955598
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple subcutaneous injections of SHR-2173 in patients with systemic lupus erythematosus (SLE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-2173 | SHR-2173 |
Timeline
- Start date
- 2024-11-24
- Primary completion
- 2025-11-10
- Completion
- 2025-11-21
- First posted
- 2025-05-02
- Last updated
- 2025-12-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06955598. Inclusion in this directory is not an endorsement.